SciBase Approves Reverse Share Split, Stock Option Program in 2026 AGM
Event summary
- SciBase's 2026 AGM approved a 1:100 reverse share split, increasing quota value per share from SEK 0.05 to SEK 5.00.
- No dividend declared for 2025; profits carried forward.
- Board re-elected: Jesper Høiland (Chairman), Robert Molander, Diana Ferro, Anna Eriksrud.
- Stock option program approved via directed issue of warrants.
- Board authorized to issue new shares, warrants, or convertible debentures with up to 20% dilution.
The big picture
SciBase's AGM decisions reflect a strategic pivot toward capital efficiency and talent retention, common in growth-stage medtech firms. The reverse share split may signal confidence in long-term valuation, while the stock option program aligns with competitive hiring pressures in the AI-driven diagnostics space. The 20% dilution authorization provides flexibility for future fundraising but introduces potential shareholder friction.
What we're watching
- Capital Structure Impact
- How the 1:100 reverse share split will affect liquidity and investor perception.
- Dilution Risk
- Whether the 20% share dilution authorization will pressure existing shareholders.
- Stock Option Performance
- The pace at which the newly approved stock option program attracts and retains talent.